Evidence map›Paper›PMID 28031971›Full record

ArticleFuture science OA2016

Company profile: BluePen Biomarkers LLC – integrated biomarker solutions.

Ian A Blair, Clementina Mesaros, Patrick Lilley, Matthew Nunez

Erratum issuedAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Ian A BlairBluePen Biomarkers LLC, 3401 Grays Ferry Avenue, Building 212, Suite 132, Philadelphia, PA 19146-2701, USA; Penn SRP Center, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; BluePen Biomarkers LLC, 3401 Grays Ferry Avenue, Building 212, Suite 132, Philadelphia, PA 19146-2701, USA; Penn SRP Center, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6160, USA.
Clementina MesarosPenn SRP Center, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Penn SRP Center, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6160, USA.
Patrick LilleyEmerald Logic, Aliso Viejo, CA 92656, USA; BluePrint Bio, Aliso Viejo, CA 92656, USA; Emerald Logic, Aliso Viejo, CA 92656, USA; BluePrint Bio, Aliso Viejo, CA 92656, USA.
Matthew NunezBluePen Biomarkers LLC, 3401 Grays Ferry Avenue, Building 212, Suite 132, Philadelphia, PA 19146-2701, USA; BluePrint Bio, Aliso Viejo, CA 92656, USA; BluePen Biomarkers LLC, 3401 Grays Ferry Avenue, Building 212, Suite 132, Philadelphia, PA 19146-2701, USA; BluePrint Bio, Aliso Viejo, CA 92656, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BluePen Biomarkers provides a unique comprehensive multi-omics biomarker discovery and validation platform. We can quantify, integrate and analyze genomics, proteomics, metabolomics and lipidomics biomarkers, alongside clinical data, demographics and other phenotypic data. A unique bio-inspired signal processing analytic approach is used that has the proven ability to identify biomarkers in a wide variety of diseases. The resulting biomarkers can be used for diagnosis, prognosis, mechanistic studies and predicting treatment response, in contexts from core research through clinical trials. BluePen Biomarkers provides an additional groundbreaking research goal: identifying surrogate biomarkers from different modalities. This not only provides new biological insights, but enables least invasive, least-cost tests that meet or exceed the predictive quality of current tests.

Indexed as

bioinformaticsbiomarkerslipidomicsmetabolomicsproteomicssystems biology

Identifiers

PMID28031971
PMCPMC5137845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.